These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 37835528)

  • 1. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.
    Gomes I; Abreu C; Costa L; Casimiro S
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
    Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
    Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer.
    Zhang C; Zhou F; Zou J; Fang Y; Liu Y; Li L; Hou J; Wang G; Wang H; Lai X; Xie L; Jiang J; Yang C; Huang Y; Chen Y; Zhang H; Li Y
    Front Oncol; 2023; 13():1322078. PubMed ID: 38293701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis.
    Takatsuka D; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Iwata H
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e175-e182. PubMed ID: 36085411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.
    Akdag G; Dogan A; Yildirim S; Kinikoglu O; Mokresh ME; Alomari O; Turkoglu E; Isik D; Sürmeli H; Basoglu T; Sever ON; Odabas H; Yildirim ME; Turan N
    Cureus; 2024 Jun; 16(6):e63362. PubMed ID: 39070363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.
    Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N
    Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
    Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer.
    Gomes I; Gallego-Paez LM; Jiménez M; Santamaria PG; Mansinho A; Sousa R; Abreu C; Suárez EG; Costa L; Casimiro S
    Cell Rep Med; 2023 Aug; 4(8):101120. PubMed ID: 37451269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2- Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies.
    Al-Qasem AJ; Alves CL; Ditzel HJ
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.
    Ferro A; Campora M; Caldara A; De Lisi D; Lorenzi M; Monteverdi S; Mihai R; Bisio A; Dipasquale M; Caffo O; Ciribilli Y
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review.
    Gao L; Shen X; He L; Wu J; Liu Y; Wang X; Shao X
    Ann Transl Med; 2022 Jan; 10(2):117. PubMed ID: 35282060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
    Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Alvarez A; Bernal AM; Anampa J
    Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
    De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
    Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD63
    Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
    Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
    Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.